Here’s What You Should Know about These Stocks in Spotlight Today

First-Quarter Miss At Dillard’s

Dillard’s, Inc. (NYSE:DDS)’s shares have retreated by more than 8% after the company reported first-quarter EPS of $2.17 on revenue of $1.54 billion. Those numbers missed the consensus by $0.35 per share and $20 million, respectively. Sales dropped 4.3% year-over-year as comparable store sales declined 5% from the same quarter last year. The disappointing sales pressured gross margin and net income to a point where the company’s EPS fell from $2.66 one year ago. Given the negative same store sales trend, shares of Dillard’s have slid by more than 14% year-to-date. Although the fundamentals are decidedly bearish, several hedge funds are betting on a turnaround. David Einhorn’s Greenlight Capital was among 17 funds tracked by Insider Monkey that held shares in Dillard’s, Inc. (NYSE:DDS) at the end of December.

Honda Reports a Surprise Loss

Honda Motor Co Ltd (ADR) (NYSE:HMC)’s stock is slightly in the red this morning after the vehicle manufacturer reported a surprise loss of around $860 million for its fiscal fourth quarter. The loss is principally due to increased costs due to the recalls of airbag inflators manufactured by Takata Corp. Honda has recalled millions of vehicles due to the defective airbag inflators and will recall millions more. Because the increased costs are a one-time event, shares of Honda Motor Co Ltd (ADR) (NYSE:HMC) are only down by 1.2%. Sales for the company rose 4.8% year-over-year for the quarter. A total of five funds that we track owned 0.1% of Honda’s float at the end of the fourth quarter.

Goldman Sachs Likes Allergan 

Allergan plc Ordinary Shares (NYSE:AGN) shares have gained over 2% after analysts at Goldman Sachs added the stock to their ‘Conviction Buy’ list. The analysts like Allergan plc Ordinary Shares (NYSE:AGN)’s strong balance sheet, rich pipeline, and $10 billion stock buyback authorization. The analysts think Allergan has more than 23% upside with a price target of $275 per share. Hedge funds are fans of Allergan too. Allergan was the most popular stock among the funds we track at the end of the last year.

Disclosure: none